BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care announced today that they will attend the American Diabetes Association’s 76th Scientific Sessions. This will be the first time that the company has attended the ADA Scientific Sessions as Ascensia Diabetes Care and marks a return to the meeting for the world renowned CONTOUR® portfolio of meters. The 76th Scientific Sessions will take place from 10-14 June, 2016 in New Orleans, Louisiana, United States.
Ascensia Diabetes Care will have the opportunity at this congress to present the new company to healthcare professionals from around the globe, continuing the heritage of more than 70 years of innovative diabetes products that started with Bayer.
Michael Kloss, CEO of Ascensia Diabetes Care, said: “We are pleased to be returning to the American Diabetes Association’s Scientific Sessions as Ascensia Diabetes Care. We see this as the ideal opportunity to tell the story of our new company and present compelling scientific data for our high quality diabetes care solutions.”
He added: “The ADA Scientific Sessions is the premier diabetes event in the U.S. and offers a unique opportunity to exchange ideas and learn about significant advances in diabetes research, treatment, and care. Ascensia wants to continue to be a trusted partner in the diabetes community and is dedicated to using innovation to offer new solutions for healthcare professionals and people living with diabetes everywhere.”
At the 76th Scientific Sessions, Ascensia Diabetes Care will be presenting key research findings, including the first usability data for the CONTOUR® NEXT ONE system, a wireless-enabled blood glucose meter that links to a smart mobile device via Bluetooth® technology, and new accuracy data for the CONTOUR® NEXT LINK 2.4 meter that is designed for use with Medtronic’s insulin pumps. The CONTOUR NEXT ONE and the CONTOUR NEXT LINK 2.4 have received CE Mark approval in Europe, where they are available in certain markets, and they are currently under 510(k) and PMA review, respectively, by the FDA in the United States, where they are not yet available.
Details of the data being presented by Ascensia Diabetes Care are as follows:
- Usability of a New Blood Glucose Monitoring System (BGMS) with a Mobile App (Poster 81-LB), Bailey T.S. et al. Sunday June 12, 2016 12:00PM - 2:00PM, during General Poster Session - Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing, Saturday, Sunday, and Monday in the Poster Hall (Halls D-E).
- Accuracy Evaluation of Six Blood Glucose Monitoring Systems often Used with Insulin Pumps following ISO 15197, Section 6.3 (Poster 898-P), Freckmann et al. Sunday June 12, 2016, Session GPS02 - Sunday General Poster Session 12:00PM - 2:00PM Poster Hall (Halls D-E).
- Accuracy of Four Systems for Self-Monitoring of Blood Glucose in the Hands of Patients and Professionals (Poster 887-P), Kamecke et al. Sunday June 12, 2016, Session GPS02 - Sunday General Poster Session 12:00PM - 2:00PM Poster Hall (Halls D-E).
The 76th Scientific Sessions also coincide with the U.S. launch of the Powered by Accuracy campaign. The Powered by Accuracy campaign includes testimonial videos. Ascensia Diabetes Care will donate $1 to the Juvenile Diabetes Research Foundation every time these videos are shared online. In addition, eligible participants from the U.S. may enter a sweepstakes on the website to win a free box of 100 CONTOUR®NEXT test strips. Visit the campaign website (www.PoweredByAccuracy.com) for more information. Eligibility requirements and restrictions apply.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping improve the lives of people with diabetes by empowering them to take charge of their health. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a simple, positive, daily difference for people with diabetes.
Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products. As a leader in diabetes care and a trusted partner, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy and compliance.
Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Following the close of the transaction in all countries, Ascensia Diabetes Care will have around 1,400 employees and operations in 38 countries.
For further information please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
CONTOUR® is a registered trademark of Ascensia Diabetes Care Holdings AG.